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advances in detection, prognosis and intervention
Ana Catalan,1,2,† Gonzalo Salazar de Pablo,2,3,† Julio Vaquerizo Serrano,2,3
Pierluca Mosillo,2,4 Helen Baldwin,2 Aranzazu Fernandez-Rivas,1 Carmen Moreno,3
Celso Arango,3 Christoph U. Correll,5,6,7,8 Ilaria Bonoldi,2,‡ and Paolo Fusar-Poli2,9,10,11,‡
1Mental Health Department - Biocruces Bizkaia Health Research Institute, Basurto University Hospital, Faculty of
Medicine and Dentistry, University of the Basque Country – UPV/EHU, Biscay, Spain; 2Early Psychosis:
Interventions and Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology
& Neuroscience, King’s College London, London, UK; 3Department of Child and Adolescent Psychiatry, Institute of
Psychiatry and Mental Health, Hospital General Universitario Gregorio Mara~non School of Medicine, IiSGM,
CIBERSAM, Complutense University of Madrid, Madrid, Spain; 4Faculty of Medicine and Surgery, University of
Pavia, Pavia, Italy; 5The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA;
6Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/ Northwell, Hempstead,
NY, USA; 7Center for Psychiatric Neuroscience, The Feinstein Institutes for Medical Research, Manhasset, NY, USA;
8Department of Child and Adolescent Psychiatry, Charite Universit€atsmedizin, Berlin, Germany; 9OASIS service,
South London and Maudsley NHS Foundation Trust, London, UK; 10Department of Brain and Behavioral Sciences,
University of Pavia, Pavia, Italy; 11National Institute for Health Research, Maudsley Biomedical Research Centre,
South London and Maudsley NHS Foundation Trust, London, UK
Background: The clinical high-risk state for psychosis (CHR-P) paradigm has facilitated the implementation of
psychosis prevention into clinical practice; however, advancements in adolescent CHR-P populations are less
established. Methods: We performed a PRISMA/MOOSE-compliant systematic review of the Web of Science
database, from inception until 7 October 2019, to identify original studies conducted in CHR-P children and
adolescents (mean age <18 years). Findings were systematically appraised around core themes: detection,
prognosis and intervention. We performed meta-analyses (employing Q statistics and I2 test) regarding the
proportion of CHR-P subgroups, the prevalence of baseline comorbid mental disorders, the risk of psychosis
onset and the type of interventions received at baseline. Quality assessment and publication bias were also
analysed. Results: Eighty-seven articles were included (n = 4,667 CHR-P individuals). Quality of studies ranged
from 3.5 to 8 (median 5.5) on a modified Newcastle–Ottawa scale. Detection: Individuals were aged
15.6  1.2 years (51.5% males), mostly (83%) presenting with attenuated positive psychotic symptoms. CHR-P
psychometric accuracy improved when caregivers served as additional informants. Comorbid mood (46.4%) and
anxiety (31.4%) disorders were highly prevalent. Functioning and cognition were impaired. Neurobiological
studies were inconclusive. Prognosis: Risk for psychosis was 10.4% (95%CI: 5.8%–18.1%) at 6 months, 20% (95%
CI: 15%–26%) at 12 months, 23% (95%CI: 18%–29%) at 24 months and 23.3% (95%CI: 17.3%–30.7%) at
≥36 months. Interventions: There was not enough evidence to recommend one specific treatment (including
cognitive behavioural therapy) over the others (including control conditions) to prevent the transition to psychosis
in this population. Randomised controlled trials suggested that family interventions, cognitive remediation and
fish oil supplementation may improve cognition, symptoms and functioning. At baseline, 30% of CHR-P
adolescents were prescribed antipsychotics and 60% received psychotherapy. Conclusions: It is possible to detect
and formulate a group-level prognosis in adolescents at risk for psychosis. Future interventional research is
required. Keywords: Psychosis; schizophrenia; clinical high-risk state for psychosis; psychosis risk; prevention;
evidence; prediction; first-episode; meta-analysis; childhood; adolescence.
Introduction
Psychotic disorders typically onset in adolescence
and early adulthood, with the peak of risk occurring
between the ages of 12 and 25 years (Radua et al.,
2018). Once the disorder onsets, the opportunities to
improve its course are limited (Millan et al., 2016).
Therefore, early intervention and particularly pre-
ventive approaches in young people with subtle signs
and symptoms of the disorder (termed ‘primary
indicated prevention’ Arango et al., 2018; Fusar-Poli,
Bauer, et al., 2019) have the potential to benefit the
lives of many young people. Primary indicated pre-
vention in individuals at clinical high-risk state for
psychosis (CHR-P) has grown exponentially over the
past two decades and has become one of the most
established preventive approaches in psychiatry
(Correll et al., 2018; Fusar-Poli, McGorry, & Kane,
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2017). There is consensus that the key elements of
the CHR-P paradigm encompass three concatenated
steps: detection, prognosis and intervention (Fusar-
Poli et al., 2020; Oliver, Radua, Reichenberg, Uher, &
Fusar-Poli, 2019). The first rate-limiting step involves
the detection (Fusar-Poli et al., 2020) of individuals
aged 12–35 who accumulate risk factors for psy-
chosis (Fusar-Poli, Tantardini, de Simone, Ramella-
Cravaro, et al., 2017; Oliver, Reilly, et al., 2019) and
functional impairment (Fusar-Poli, Rocchetti, et al.,
2015), seeking help (Falkenberg et al., 2015) at
specialised mental health clinics (Fusar-Poli,
Estrade, et al., 2019). In the second step, these
individuals are assessed with specific psychometric
interviews which discriminate between thosemeeting
CHR-P criteria (Table 1), those already psychotic (i.e.
above threshold) and those not at risk (Fusar-Poli,
Cappucciati, et al., 2015), thus formulating a group-
level prognosis (Fusar-Poli, Hijazi, Stahl, & Steyer-
berg, 2018). In the final third step, CHR-P individuals
are offered need-based interventions and, if avail-
able, specific indicated preventive interventions
(Fusar-Poli, Davies, Solmi, et al., 2019).
The CHR-P paradigm is, therefore, ‘transitional’ in
natureand ‘integrated’ (Fusar-Poli, 2019) across child
and adolescent, and adult mental health services,
bridging the existing gap between the traditional two-
tier system. While advancements in detection, prog-
nosis and interventions in adult CHR-P populations
have recently been appraised in an umbrella review
(Fusar-Poli et al., 2020), the specific advancements
that pertain to child and adolescent CHR-P individu-
als are less clear. In fact, most of the evidence focuses
onadultCHR-P samples,with relatively little research
surrounding children and adolescents. Investigating
the CHR-P paradigm in children and adolescents
poses additional empirical challenges with respect to
their detection, prognosis and interventions. Original
studies in CHR-P children and adolescents report
inconclusive findings across these three mainstream
clinical research areas (Schlosser et al., 2012; Welsh
& Tiffin, 2014).
This study addresses these gaps and advances
understanding in the field of prevention of psychosis
for children and adolescents at CHR-P, summarising
the available evidence relating to detection, prognosis
and intervention in this field. The research in these
areas has substantial potential to increase the ben-
efits of the early intervention in psychosis approach
(Fusar-Poli et al., 2020). The systematic appraisal of
the evidence is also complemented by meta-analytic
analyses regarding each of the three core compo-
nents. The results are discussed critically to advance
clinical knowledge and inform future research.
Methods
This review was conducted following the guidelines of the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA, Table S1) (Moher, Liberati, Tetzlaff, &
Altman, 2009) and Moose checklist (Table S2) (Stroup et al.,
2000), following EQUATOR Reporting Guidelines (Altman,
Simera, Hoey, Moher, & Schulz, 2008).
Search strategy and selection criteria
A systematic search strategy was adopted to identify relevant
articles, and three independent researchers implemented a
two-step literature search (Appendix S1). Articles identified
were screened as abstracts; those not meeting inclusion
criteria were then excluded, and the full texts of the remaining
articles were assessed for eligibility.
The following inclusion criteria were used to select the
articles: (a) original studies, (b) conducted in individuals
meeting CHR-P criteria as defined by the following standard-
ised criteria (Appendix S2) and (c) conducted in children and
adolescents, empirically defined through a mean age of the
sample of <18 years, in line with previous systematic reviews
in this population (Tor et al., 2018). Exclusion criteria were as
follows: (a) reviews, clinical cases, conference proceedings and
study protocols, (b) studies that did not formally assess and
select participants with established CHR-P instruments and (c)
studies in languages other than English.
Outcome measures and data extraction
We extracted the following data from each study: first author,
year of publication, country, study type and design (cohort,
cross-sectional, randomised controlled trial – RCT – natural-
istic), sample size of CHR-P and comparison group, topic, type
of comparison group, mean age (SD and range when available),
% of male CHR-P individuals, instruments used to define the
CHR-P criteria, quality assessment and key findings.
Strategy for data synthesis
We provided a narrative synthesis of the systematic review
from the included studies, structured around core themes:
detection (characteristics of the CHR-P state, clinical comor-
bidity, functioning and quality of life, cognition, neuroimaging,
biochemistry, electrophysiology), prognosis (overall prognosis
and prediction of outcomes) and interventions. The narrative
findings were complemented by specific meta-analyses that
were performed when enough studies were available within
each domain. The meta-analyses addressed: (a) the proportion
of individuals in each CHR-P subgroup, (b) the prevalence of
comorbid nonpsychotic mental disorders at baseline, (c) the
risk of psychosis onset in this population and (d) the type of
indicated preventive interventions received at baseline. The
proportion of individuals in each of the three CHR-P subgroups
(attenuated psychotic symptoms, APS; brief-limited-intermit-
tent psychotic symptoms, BLIPS/BIPS; and genetic risk and
deterioration syndrome, GRD) was defined according to estab-
lished criteria (Fusar-Poli, Cappucciati, Bonoldi, et al., 2016;
Fusar-Poli, Cappucciati, Borgwardt, et al., 2016; Fusar-Poli,
Cappucciati, de Micheli, et al., 2017). The prevalence of
baseline comorbid nonpsychotic disorders was indexed as
the proportion of CHR-P individuals with comorbid nonpsy-
chotic ICD/DSM (any version) mental disorders. The risk of
developing psychosis in CHR-P children and adolescents at 6,
12, 24 and 36 or more months was ascertained using ICD/
DSM (any version) or psychometric operationalisation (i.e.
CHR-P-based) of psychosis onset. The types of treatments
received at baseline were analysed, including psychotherapy or
psychopharmacology as reported by each individual study. For
all of these meta-analyses, additional inclusion criteria were as
follows: (a) nonoverlapping samples and (b) availability of ≥3
independent studies reporting on the same outcome. Overlap-
ping was defined as studies that used the same sample of
individuals at CHR-P.
© 2020 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for
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Since high heterogeneity was expected, random-effects
meta-analyses were conducted (DerSimonian & Laird,
1986). Heterogeneity among study point estimates was
assessed using Q statistics. The proportion of the total
variability in the effect size estimates was evaluated with
the I2 index (Lipsey & Wilson, 2000). Publication bias was
assessed for the risk of psychosis onset meta-analysis by
inspecting meta-funnel plots and assessing Egger´s test
(Egger, Davey Smith, Schneider, & Minder, 1997). For the
other meta-analyses (comorbid nonpsychotic disorders, types
of treatments received at baseline and the proportion of
individuals in each of the three CHR-P subgroups), we did
not use the Egger test because studies included in the meta-
analyses of proportions are noncomparative, thus there are
no ‘negative’ or ‘undesirable’ results or study characteristics,
such as significance levels, that may have biased publica-
tions (Maulik, Mascarenhas, Mathers, Dua, & Saxena, 2011).
We also performed sensitivity analyses for each of the meta-
analyses, comparing the studies that included exclusively
CHR-P participants <18 years versus those that included
some participants ≥18 years of age. Finally, we conducted
meta-analytical regressions to evaluate the association
Table 1 Core definitions of the CHR-P state, which include the ultra-high risk and basic symptoms domains (adapted from Fusar-
Poli et al. 2013)
CHR-P subgroup (acronym);
2 years risk of psychosis (95%
CI) (Fusar-Poli, Cappucciati,
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Abbreviations: CAARMS, Comprehensive Assessment of the At-Risk Mental State; NA, no applicable; SIPS/SOPS, Structured
Interview for Psychosis-Risk Syndromes; SPI-A, Schizophrenia Proneness Instrument, adult version; SPI-CY, Schizophrenia
Proneness Instrument, child and youth version.
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between our outcomes and the quality of the studies. All
analyses were 2-sided, with a = .05. Comprehensive Meta-
Analysis (CMA) V3 software (Borenstein, Hedges, Higgins, &
Rothstein, 2013) was used.
Quality assessment
Study quality was assessed in all the included studies. A
modified version of the Newcastle–Ottawa scale for cross-
sectional and cohort studies, ranging from 0 to 8, was used to
remain consistent with previous studies (Fusar-Poli, Tantar-
dini, de Simone, Ramella-Cravaro, et al., 2017; Salazar de
Pablo, Catalan, & Fusar-Poli, 2019) (Table S3).
Results
Of15,577articles identified, 87articleswere included
inthesystematicreview(n = 4,970CHR-Pindividuals)
(Figure 1). Forty-four studies were from the United
States (50.6%), 35 from Europe (40.3%), 6 from Aus-
tralasia (6.8%) and2 fromCanada (2.3%). The sample
size of the studies ranged from 7 to 358; the age of
included participants ranged from 5 to 35 years. Ten
studies included samples with only participants aged
under 18 years. Only eight studies included partici-
pants under 12 years; as such, hereafter we use the
term adolescents to refer to the results of our search.
Detection
Characteristics of the CHR-P state. Systematic
review: Sixteen studies reported on general charac-
teristics of the CHR-P state in adolescents. The mean
age of CHR-P individuals across the included studies
was 15.6  1.2 years, and 51.5% were males. Alto-
gether, 72 studies employed the SIPS/SOPS, 19 the
CAARMS, 6 the BSABS, 3 the SPI-CY and 4 the PANSS
(10 studies used more than one instrument). The
proportion of individuals meeting CHR-P criteria was
16%–36% inmental health settings (Koren et al., 2019,
Lo Cascio et al., 2017), including 23.6% in adolescent
inpatientsettings (Gerstenbergetal.,2015)and13%in
nonhelp-seeking adolescents with disruptive beha-
viours (Manninen et al., 2014). From a psychometric
perspective, four studies focused on the validation of
CHR-P assessment scales in adolescents across differ-
ent languages (Fux, Walger, Schimmelmann, &
Schultze-Lutter,2013;Klineetal.,2012;Pelizza,Azzali,
et al., 2019; Thompson, Kline, Reeves, Pitts, & Schiff-
man, 2013). One study reported on the iPQ-16 (the
ItalianVersionofthe16-itemProdromalQuestionnaire)
screening tool against the CAARMS (Pelizza, Azzali,
etal.,2019).AnotherstudycomparedthePrimeScreen,
theYPARQ-B (YouthPsychosisAt-RiskQuestionnaire-
Brief) and the PQB (Prodromal Questionnaire-Brief)
scales against the SIPS (Kline et al., 2012). Finally, two
studies (Thompson et al., 2013, 2014) compared the
BASC-2 (Behaviour Assessment System for Children,
SecondEdition)with theSIPS.Allof theseprescreening
instruments demonstrated good discriminant validity
[accuracy ranging from 61% (Kline et al., 2012) to 90%
(Fux et al., 2013)] against the gold standard CHR-P
instruments in this age range (Table S4).
In adolescents, the raters’ agreement on the CHR-P
designation (on the SIPS) between self-report data
and family reports was moderate (j = .5) (Golembo-
Smith, Bachman, Senturk, Cannon, & Bearden,
2014). The accuracy of identification of cases at risk
of psychosis differed when information was collected
from the CHR-P individuals themselves (sensitivity:
68%, specificity: 79% and accuracy: 73%) compared
to their parents (sensitivity: 65%, specificity: 76%
and accuracy: 70%), and was greatly improved upon
when both informants were consulted (sensitivity:
82%, specificity: 79% and accuracy: 81%) (Thomp-
son et al., 2014). Another study (Simeonova,
Nguyen, & Walker, 2014) indicated that the Child
Behaviour Checklist (CBCL) scale could differentiate
CHR-P individuals from the general population. This
instrument is a commonly used tool in child and
adolescent psychiatry. The CBCL parent-report scale
was used to assess behavioural problems and com-
petencies of participants. The measure includes 118
items rated from 0 (not at all typical of the child) to 2
(often typical of the child) and is appropriate for use
in those aged 4–18 years. The CBCL clinical scales
contain the Total Problems scale, two ‘broadband’
dimensions (internalising problems and externalis-
ing problems) and eight cross-informant syndromes
(anxious/depressed, withdrawn/depressed, somatic
complaints, social problems, thought problems,
attention problems, delinquent behaviour and
aggressive behaviour). The CBCL also yields a mea-
sure of social competencies – the total competence
scale (composed of the activities, social and school
subscales).
From a broader clinical perspective, CHR-P ado-
lescents typically presented with attenuated psy-
chotic symptoms (Lo Cascio et al., 2016), predated
by negative symptoms (Meyer et al., 2005). A further
study (Spada et al., 2016) sought to describe a
subgroup of CHR-P individuals defined based on
negative psychotic symptoms, finding that this
potential category was highly prevalent (18% of
adolescents meeting CHR-P criteria). Although basic
symptoms were suggested to be useful in the detec-
tion of CHR-P adolescents, only one study reported
on this (Lo Cascio et al., 2016).
Other studies focused on behavioural characteris-
tics of this population and reported that CHR-P
individuals experienced a more external locus of
control and more social stress (Millman et al., 2017)
than healthy controls (HC), associated with greater
severity of APS (Millman et al., 2018). Four studies
focused on the influence of family relationships in
adolescents at CHR-P (O’Brien et al., 2008; Salinger,
O’Brien, Miklowitz, Marvin, & Cannon, 2018; Tsai
et al., 2015), indicating impairments in self-reliance
and relations with their parents (Thompson et al.,
2015). Lower familial warmth (measured using self-
© 2020 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for
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report questionnaires) was associated with an
increased severity of attenuated positive psychotic
symptoms (Tsai et al., 2015). Behaviours and atti-
tudes towards mental disorders were found to be
more negative in parents of adolescents at CHR-P
compared to parents of adolescents at risk for
bipolar disorder (Salinger et al., 2018).
Finally, there were more severe behavioural dis-
turbances in CHR-P adolescents with a family
history of psychiatric disorders compared to those
without such a family history (Simeonova, Lee, &
Walker, 2015) (Table S4).
Meta-analysis: The meta-analysis on the type of
CHR-P subgroup identified 20 independent studies,
showing that the vast majority of young CHR-P
patients fulfilled APS criteria (82.6%, 95%CI:
75.0%–88.3%), followed by GRD criteria (8.5%,
95%CI: 4.8%–14.4%), and then BLIPS criteria
(6.7%, 95%CI: 4.2%–10.5%, Table S5, Figures S1-
S3). Heterogeneity across the studies included was
statistically significant (I2: 34.0–92.0, p < .001) in
all the primary analyses and sensitivity analyses,
except for the BLIPS sensitivity analysis (I2 = 22.6,
p = .25). The sensitivity analyses comparing the
studies that included exclusively underage CHR-P
participants versus those that included individuals
≥18 years did not find differences across these
subgroups, except for the GRD subgroup, in which
a higher proportion of GRD was found in studies
including only individuals <18 years of age (15%) vs
those including individuals aged ≥18 (7%)
(Table S6).
Clinical comorbidity in the CHR-P state. System-
atic review: Six studies had a primary focus on the
investigation of comorbidities in CHR-P (Gerstenberg
et al., 2015; Kline et al., 2016; Morelli et al., 2019;
Records identified 
through database 
searching N = 15574












Articles excluded during 


















manually N = 3




*Based on a population 
other than CHR subjects 
(N = 19); 
*Review data or theoretical 
articles or other types of 
studies (N = 9);
*Mean age older than 18 
(N = 8);
*Others (N = 2).
Studies included in 
the meta-analyses
N= 24
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart outlining the study selection process
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Pelizza, Poletti, et al., 2019; Pitzianti et al., 2019;
Stain et al., 2018). Comorbidity was frequent (from
46.4% to 7%) in adolescents at CHR-P (Table S7).
16 (76.2%) studies used structured instruments,
including the Schedule for Affective Disorders and
Schizophrenia for School-Age Children scale (K-
SADS) (11 studies, 52.4%) and the SCID (7 studies,
33.3%). Five studies (23.8%) used clinical criteria,
including DSM-IV criteria (3 studies, 14.3%) and
ICD-10 criteria (3 studies, 14.3%).
Some studies revealed that substance use was
associated with higher levels of depression (Stain
et al., 2018). Young people with substance use living
in rural areas were more likely to seek help from
community mental health services rather than from
primary health care and were more likely to be
prescribed antidepressants than youths living in an
urban environment (Stain et al., 2018). Neurological
soft signs were also more frequently present in CHR-
P versus HC group (Pitzianti et al., 2019). The
prevalence of previous traumatic events was high
(ranging from 63.2% to 85.0%) in adolescents at
CHR-P (Kline et al., 2016; Morelli et al., 2019). Other
studies indicated that adolescents at CHR-P pre-
sented with elevated rates of suicidal attempts
compared to HC (17.5% vs. 2.5%) (D’Angelo et al.,
2017; Pelizza, Poletti, et al., 2019) (Table S7).
Meta-analysis: Mood disorders were the most fre-
quent comorbidity in the sample (46%, 95%CI: 39%–
53%), followed by anxiety disorders (31%, 95%CI:
24%–40%) and behavioural disorders (24%, 95%CI:
16%–34%). Heterogeneity across the included stud-
ies was statistically significant for mood disorders,
bipolar disorders, anxiety disorders, ADHD, perva-
sive developmental disorder (PDD) and other comor-
bid conditions (I2: 72.4–84.8) (Table 2). Sensitivity
analyses (Table S8) comparing the studies that
included exclusively underage participants at CHR-
P versus those that were ≥18 years of age showed a
higher prevalence of bipolar disorder (BD) (p = .012),
and PPD (p = .004) but a lower prevalence of anxiety
disorders (p < .001) in studies including only indi-
viduals <18 years of age.
Functioning and quality of life in the CHR-P
state. Systematic review: Seven studies investi-
gated functioning and quality of life in CHR-P
adolescents. The CHR-P group presented poorer
functioning scores (Carrion et al., 2013; Dolz, Tor,
Portoles, et al., 2018; Velthorst et al., 2018) and
health-related quality of life (Nitka, Richter, Parzer,
Resch, & Henze, 2016) compared with HC. An older
presentation of CHR-P (15–18 years) (Ribolsi et al.,
2017), higher levels of emotional involvement, pos-
itive remarks and warmth from caregivers were
associated with better social functioning (O’Brien
et al., 2006). Conversely, dyskinesia was associated
with greater impairments in psychosocial function-
ing (Mittal et al., 2011) (Table S9). Adolescents at
CHR-P showed higher anhedonia scores and anhe-
donia were correlated with impaired role functioning
and negative symptoms (Pelizza, Poletti, et al., 2019).
Cognition in the CHR-P state. Systematic
review: Eight studies investigated cognition. The
CHP-P state in adolescents was related to impair-
ments in neurocognitive performance compared with
HC (D’Angelo et al., 2019; Koren et al., 2019;
Woodberry et al., 2010), including poor visual form
perception (Ilonen, Heinimaa, Korkeila, Svirskis, &
Salokangas, 2010), mild-to-moderate executive
impairments (Ilonen et al., 2010) in working memory
(Smith, Park, & Cornblatt, 2006), labelling of facial
expressions (van Rijn et al., 2011a), and ability to
recognise facial identity (van Rijn et al., 2011a).
CHR-P adolescents experienced more maladaptive
beliefs (Welsh, Cartwright-Hatton, Wells, Snow, &
Tiffin, 2014) and difficulties in verbalising their own
emotions (van Rijn, Schothorst, Wout, Sprong, Zier-
mans, et al., 2011). Learning deficits were associated
with more symptoms and poorer functioning (Waltz
et al., 2015) (Table S10).
Neuroimaging, biochemistry and electrophysiology
in the CHP-P state. Systematic review: Thirteen
studies investigated neuroimaging, biochemistry or
electrophysiology in CHR-P adolescents, finding a
Table 2 Meta-analytical proportion of CHR-P adolescents with DSM/ICD comorbid mental disorders
Comorbid disorder N of studies Total sample Proportion of comorbid disorder 95% CI Q df I2 p
MDD/ mood disorder 20 980 0.46 0.39 0.53 77.13 19 75.37 <.001
BD 4 172 0.19 0.08 0.39 15.74 3 80.94 .001
Anxiety disorders 18 952 0.31 0.24 0.40 111.55 17 84.76 <.001
OCD 4 204 0.13 0.07 0.22 5.15 3 41.81 .161
Personality disorders 5 225 0.11 0.08 0.16 0.75 4 0.00 .945
ADHD 10 444 0.22 0.13 0.36 57 9 84.3 <.001
PDD 5 207 0.14 0.05 0.34 23.04 4 82.64 <.001
Behavioural disorder 7 210 0.24 0.16 0.34 11.55 6 48.0 .073
SUD 5 270 0.07 0.05 0.11 2.63 4 <0.001 .621
Other 12 550 0.17 0.12 0.26 39.83 11 72.38 <.001
Abbreviations: ADHD, attention deficit hyperactivity disorder; BD, Bipolar disorder; MDD, Major depressive disorder; OCD,
Obsessive compulsive disorder; PDD, Pervasive developmental disorder; SUD, Substance use disorder.
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higher number of biochemical alterations compared
to HC, including polyunsaturated fatty acids (PUFA)
deficits (Rice et al., 2015), lower testosterone levels
(van Rijn et al., 2011b) and increased cortisol
secretion (Moskow et al., 2016). Salivary cortisol
secretion was not associated with the severity of
overall positive symptoms but was related to higher
levels of suspiciousness, anxiety and impaired stress
tolerance (Corcoran et al., 2012).
Structural neuroimaging in this population yielded
inconclusive findings. One study found no differ-
ences between CHR-P adolescents and HC in terms
of brain volume or white matter density (Ziermans
et al., 2009). Another study investigated subcortical
volumes to distinguish between CHR-P and HC
individuals, but the imaging biomarker had low
sensitivity (59%) and specificity (68%) (de Wit et al.,
2017). A significant association was found between
subcortical volumes and poorer levels of functioning
(de Wit et al., 2017) and higher significant symptoms
(Bartholomeusz et al., 2014; Demro et al., 2017; de
Wit et al., 2016, 2017).
Amygdala volume was positively correlated with
sadness recognition in CHR-P populations (Bartho-
lomeusz et al., 2014), while greater cortical thickness
in the frontal and insular cortex was associated with
higher levels of self-reflectiveness and theory of mind
ability (Buchy, Stowkowy, Macmaster, Nyman, &
Addington, 2015).
Only a few electrophysiological studies were found,
indicating changes in prepulse inhibition (Ziermans
et al., 2012) and smaller N100 amplitudes in CHR-P
individuals compared with HC (Gonzalez-Heydrich
et al., 2015, 2016) (Table S11).
Prognosis
Overall prognosis/risk of psychosis. Systematic
review: Between 36% (Schlosser et al., 2012) and
49.1% (Ziermans, Schothorst, Sprong, & van Enge-
land, 2011) of adolescents at CHR-P remitted from
their initial CHR-P state after 2 years, and only 40%
did soafter 6 years (deWit et al., 2014). Lower levels of
baseline negative and mood symptoms were associ-
ated with higher chances of recovery at 2 years
(Schlosseretal.,2012).Themostsignificantreduction
in attenuated positive symptoms occurred within the
first two years after the CHR-P diagnosis (Armando
et al., 2015) (Table S12). The intensity of the distress
associated with anxiety and substance use was also
related to an increased risk of psychosis (Rapado-
Castro, McGorry, Yung, Calvo, & Nelson, 2015).
The CHR-P population had a greater deviation of
predicted age from the individuals´ chronological age
(brain age–chronological age; brain age gap) than HC
(Chung et al., 2018). A higher brain age gap between
the brain age and the chronological age was associ-
ated with a higher risk of developing psychosis in
adolescents at CHR-P (Chung et al., 2018).
Furthermore, a smaller putamen volume was asso-
ciated with higher levels of dyskinesia, while base-
line caudate and putamen volumes distinguished
CHR-P individuals who converted to psychosis from
those who did not (Mittal et al., 2010).
Meta-analysis: Altogether, 23 independent studies
reported on the risk of psychosis onset at follow-up
(mean duration: 27 months  24.1). The meta-ana-
lytical risk of psychosis was 10.4% (95%CI: 5.8%–
18.1%) at 6 months, 20% (95%CI: 15%–26%) at
12 months, 23.0% (95%CI: 18.0%–29.0%) at
24 months and 23.3% (95%CI: 17.3%–30.7%) at
36 months of follow-up (Figure 2). Egger’s test did
not reveal significant publication bias at any time
point (Figures S4-S11). Heterogeneity was signifi-
cant at 6-month follow-up (Q = 9.284, p = .026) but
not at 12-, 24-, or 36-month follow-up (all p > .05).
Sensitivity analyses found no statistically significant
differences between studies that included only indi-
viduals <18 years old and those that also included
individuals ≥18 years old (all p > .05) (Table S13).
Prediction of outcomes in CHR-P. Systematic
review: Positive remarks and warmth within fam-
ilies predicted longitudinal improvement for young
individuals at CHR-P (O’Brien et al., 2008). Con-
versely, conflictual communications between indi-
viduals at CHR-P and their families were related to
an increase in positive attenuated psychotic symp-
toms (O’Brien et al., 2009). The individuals at CHR-P
who converted to psychosis had higher baseline
severity of attenuated psychotic symptoms (Sime-
onova, Attalla, Trotman, Esterberg, & Walker, 2011)
compared with those not developing psychosis. The
clinical improvement over time in this CHR-P popu-
lation was associated with increased prepulse inhi-
bition (Ziermans, Schothorst, Magnee, van
Engeland, & Kemner, 2011) (Table S14). Self-re-
ported internalising and thought content problems
were associated with more frequent hospital treat-
ments for mood and conduct disorders in a cohort of
young offenders at CHR-P (Manninen et al., 2014).
The social and role functioning, which was
impaired early (12 years), remained stable in those
who developed psychosis but improved in those not
developing psychosis (Velthorst et al., 2018). Neu-
rocognitive impairments were also more severe in
CHR-P individuals who converted to psychosis than
those who did not (Woodberry et al., 2013), with a
significant impairment in olfactory identification
(Woodberry et al., 2010). Some studies described a
positive relationship between functional activation
during working memory in the frontal lobe and age in
CHR-P, while the inverse was observed in the HC
(Karlsgodt, van Erp, Bearden, & Cannon, 2014).
Finally, low (1–4 times) to moderate (≥20 times)
lifetime cannabis use was not associated with poorer
functioning (Auther et al., 2012).
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Interventions
Systematic review. Thirteen studies investigated
interventions (any design) in this subgroup: five were
naturalistic, and eight were RCT.
Among the naturalistic studies, family therapy was
associated with an improvement in CHR-P symp-
toms and functional outcomes (O’Brien et al., 2007),
as well as levels of self-reported depression and
hopelessness at 18 months (Grano et al., 2016). A
further naturalistic study showed an improvement in
the level of dysphoric mood and tolerance to normal
stress after 4 weeks of biofeedback therapy (McAus-
land & Addington, 2018). Only two psychopharma-
cologic naturalistic studies were found in this
population (Bowie, McLaughlin, Carrion, Auther, &
Cornblatt, 2012; Cornblatt et al., 2007). One study
suggested that antidepressants were more effective
than second-generation antipsychotics on neurocog-
nition, verbal learning and attention after 6 months
(Bowie et al., 2012). Another study found higher
levels of disorganisation symptoms in individuals
treated with antipsychotics compared with those
taking antidepressants (Cornblatt et al., 2007).
Antidepressants were also better tolerated than
antipsychotics. Transition to psychosis occurred
mostly >6 months after stopping antipsychotics
against medical advice (Cornblatt et al., 2007).
Among the identified RCTs, two tested the efficacy
for preventing psychosis (Stain et al., 2016). One
compared cognitive behavioural therapy versus
nondirective reflective listening therapy in a group
of youths at CHR-P (Stain et al., 2016). The transi-
tion risk was 5% in the experimental group, without
any conversion in the HC group. The second RCT
found that omega-3 fatty acid supplementation
reduced the risk of transitioning to psychosis
(Amminger et al., 2010), alternative psychopathology
and poor functioning (Amminger et al., 2010, 2013;
Mossaheb et al., 2013) at 12 weeks with no sub-
stantial side effects or impact on the levels of
triglycerides (Mossaheb et al., 2018) (Table S15).
Other RCTs investigated family therapy, which
was associated with decreased levels of criticism
from mothers (Tsai et al., 2015) at 12 months, and
decreased severity of attenuated psychotic symp-
toms (Miklowitz et al., 2014) at 6 months. Another
RCT employed computer-assisted cognitive remedi-
ation, showing improved attention, immediate and
delayed memory, and general psychopathology, as
well as social–occupational functioning, compared
with computer games at 8 weeks (Holzer et al.,
2014).
Meta-analysis. The meta-analytical results
revealed that 30.4% of the adolescents at CHR-P
were prescribed antipsychotics at baseline (95%CI:
22%–40%), 27.1% antidepressants (95%CI: 22%–
33%), 11.0% benzodiazepines (95%CI: 3%–32%) and
15.1% other psychotropic medication (95%CI: 8%–
27%); 60.4% received some type of psychotherapy
(95%CI: 26%–87%). Heterogeneity (I2) across the











Follow-up n of studies* Sample size Cumulative risk of 
psychosis (95% CI)
Q df I2 P
6-month 4 348 0.10 (0.058-0.181) 9.28 3 67.69 0.026
12-month 7 525 0.198 (0.146-0.263) 12.44 6 51.76 0.053
24-month 7 681 0.230 (0.180-0.290) 12.24 6 50.99 0.057
36-month 5 239 0.233 (0.173-0.307) 6.24 4 27.17 0.240
Figure 2 Meta-analytical cumulative risk of psychosis onset in adolescents meeting a CHR-P state over time [Colour figure can be viewed
at wileyonlinelibrary.com]
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included studies was statistically significant
(p < .001) and ranged from 67.8 (antidepressants)
to 94.0 (benzodiazepines) (Table 3). The sensitivity
analyses comparing the studies that included exclu-
sively underage CHR-P participants versus those
that also included individuals ≥18 did not reveal
differences (Table S16).
Meta-regressions
A higher quality of the included studies (b = .378,
p = .044) was associated with a higher prevalence of
anxiety disorders. Lower quality of the included
studies (b = .861, p = .023) was associated with a
higher prevalence of bipolar disorders. There was no
significant association between the quality of the
included studies and any other DSM/ICD comorbid
mental disorder. There was no significant associa-
tion between the quality of the included studies and
the presence of any CHR-P subgroup, the transition
to psychosis in any time period or any intervention
outcome (all p > .05) (Table S17).
Quality assessment. The quality rating of the
studies ranged from 3 to 8 for the cohort studies
(median = 6) (Table S18) and from 3.5 to 8 for the
cross-sectional studies (median = 5.5) on a modified
version of the Newcastle–Ottawa scale (Table S19).
Discussion
We systematically reviewed 87 studies, expanding
the knowledge obtained from the 48 studies previ-
ously described in the only other systematic review
on this topic (Tor et al., 2018).
We have provided the first meta-analytical evi-
dence of the three key components of CHR-P
research: detection, prognosis and intervention.
Transition risk was 10.4% at 6 months, 20% at
12 months, 23% at 24 months and 22% at
≥36 months. When sensitivity analyses were
restricted to samples including only underage par-
ticipants, the transition risk was 20% at 12 months,
23% at 24 months and 25% at ≥36 months. Overall,
we found a similar transition risk in adolescents at
CHR-P (22% after 36 months) to that observed in
adult samples (22%) (Fusar-Poli et al., 2020). Inter-
estingly, a recent meta-analysis focusing on the
DSM-5 APS designation found a comparable 23%
transition risk at 36 months (Salazar de Pablo et al.,
2019). It could be that the relatively lower incidence
of psychosis risk observed in adolescents at CHR-P
is counterbalanced by more effective risk enrichment
strategies (Fusar-Poli, Rutigliano, et al., 2016;
Fusar-Poli, Schultze-Lutter, et al., 2016). For exam-
ple, most adolescent samples included in the current
study were recruited through inpatient or outpatient
mental health units or programmes, which are well
known to be associated with a higher level of risk
enrichment (Fusar-Poli, Rutigliano, et al., 2016;
Fusar-Poli, Schultze-Lutter, et al., 2016). Further-
more, the transition to psychosis may increase in the
long-term, given that adolescents may experience an
extended period of risk compared with adult popu-
lations (Dominguez et al., 2013). Beyond the risk for
the development of psychosis, 60% of adolescents at
CHR-P did not recover and remained symptomatic
after six-year follow-up (de Wit et al., 2014) with
negative consequences in terms of functioning and
comorbidities. In particular, lower levels of negative
and mood symptoms were linked to higher possibil-
ities of recovery (Schlosser et al., 2012), suggesting
that negative and mood symptoms should become
targets of future interventions in this area. Further-
more, an early presentation before the age of 15 was
associated with worse social functioning (Ribolsi
et al., 2017). In adults at CHR-P, the unfavourable
trajectories (any recurrence, relapse, no-remission
and transition to psychosis) represent 57.1% (Polari
et al., 2018).
Most studies retrieved (59.3%) focused mainly on
aspects related to the detection of CHR-P individu-
als. Several psychometric instruments are currently
available to detect these individuals such as the SIPS
(Millman et al., 2017; Salinger et al., 2018) or the
CAARMS (Yung, Yuen, Phillips, Francey, & McGorry,
2003). However, additional psychometric instru-
ments have been developed for this particular group
under 18 years, such as the SPI-CY (Fux et al., 2013;
Pelizza, Azzali, et al., 2019). The prognostic accuracy
of SPI-CY and i-PQ16 (16-item prodromal question-
naire) in adolescents was good (sensitivity: 0.7–0.83,
specificity: 0.73–0.86) (Fux et al., 2013; Pelizza,
Azzali, et al., 2019), which is comparable to findings
in adult populations (Fusar-Poli, Cappucciati, et al.,
2015). Regarding the different CHR-P subgroups,
our meta-analysis showed that most (82.6%) CHR-P
individuals fulfilled APS criteria, concordant with the
Table 3 Meta-analysis of proportion of CHR-P adolescents receiving treatments at baseline




treatment used 95% CI Q df I2 p Egger test
Antipsychotics 15 737 0.30 0.22 0.40 76.85 14 81.78 <.001 0.32
Antidepressants 17 858 0.27 0.22 0.33 48.69 16 67.80 <.001 0.02
Benzodiazepines 11 592 0.11 0.03 0.32 166.65 10 94.0 <.001 0.13
Other psychotropic 9 521 0.15 0.08 0.27 54.27 8 85.26 <.001 0.21
Psychotherapy 6 270 0.60 0.26 0.87 71.72 5 93.03 <.001 0.34
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previous meta-analysis including adults (85%)
(Fusar-Poli, Cappucciati, Borgwardt, et al., 2016).
However, the proportion of GRD appeared higher in
youth at CHR-P (8%) compared to the previous meta-
analysis, including an adult population (5%) (Fusar-
Poli, Cappucciati, Borgwardt, et al., 2016). This
difference may be due to the fact that screening
families where a parent is affected with a psychotic
disorder is relatively more frequent in paediatric
settings, hence increasing the proportion of those
meeting this familial risk CHR-P subgroup. However,
the proportion of BLIPS (6.7%) appeared lower than
that reported in the adult CHR-P population (10%)
(Fusar-Poli, Cappucciati, Borgwardt, et al., 2016).
This difference may be due to the lower incidence of
psychotic disorders in younger populations (Fusar-
Poli, Davies, Rutigliano, et al., 2019). Some studies
suggested that refined CHR-P subgroups may be
specifically needed in this young population (Spada
et al., 2016), for example, an attenuated negative
symptom subgroup (Fusar-Poli & Borgwardt, 2007).
Another core theme was the implication of the family
for the detection of the CHR-P paediatric population.
Several authors described a better recognition of the
CHR-P state when the caregiver was involved in
assessment procedures (Golembo-Smith et al.,
2014; Thompson et al., 2014), highlighting the
importance of family as a source of clinical informa-
tion in this age group.
We also confirmed, at a meta-analytical level, that
comorbid mental disorders were frequent in adoles-
cents at CHR-P, particularly mood and anxiety
disorders. The prevalence of mood disorders was
similar to those from a previous meta-analysis
conducted in CHR-P adults (41%) (Fusar-Poli, Nel-
son, Valmaggia, Yung, & McGuire, 2014). Con-
versely, the proportion of comorbid anxiety
disorders seemed to be higher in adolescents
(31.4%) compared to rates found in the previous
meta-analysis of adult patients (15%) (Fusar-Poli
et al., 2014). Anxiety disorders are the most preva-
lent mental health concern in the adolescent popu-
lation (Siegel & Dickstein, 2012), and findings
suggest that the onset of the first anxiety disorder
is clearly in childhood (Kessler et al., 2005).
Overall, these findings suggest that psychopathol-
ogy in adolescents meeting CHR-P criteria is charac-
terised by transdiagnostic features that cut across
different mental disorders (Fusar-Poli et al., 2020).
Furthermore, adolescents with CHP-P features
reported more social stress (Millman et al., 2018),
previous traumatic events (Kline et al., 2016; Morelli
et al., 2019) and a higher risk of suicidal attempts
(Pelizza, Poletti, et al., 2019) compared to matched
HC. The presence of these features, if coupled with
comorbid mental disorders, may trigger an increased
risk of psychosis (Rapado-Castro et al., 2015). Con-
sistent with these findings, CHR-P adolescents pre-
sented with poorer functioning (Carrion et al., 2013;
Dolz, Tor, de la Serna, et al., 2018; Velthorst et al.,
2018), quality of life (Nitka et al., 2016) and moderate
impairments in neurocognitive performance com-
pared to HC (D’Angelo et al., 2019; Koren et al.,
2019;Woodberry et al., 2010), similar to observations
in adult CHR-P populations (Fusar-Poli et al., 2012).
Few studies explored neurobiological correlates of
the CHR-P state in adolescents. Paediatric CHR-P
participants showed lower testosterone (van Rijn
et al., 2011b) and increased morning salivary corti-
sol level (Moskow et al., 2016) compared to HC.
Contrary to brain morphological abnormalities
observed in adults at CHR-P (Harrisberger et al.,
2016; Walter et al., 2016), structural alterations
have not been robustly confirmed in adolescents at
CHR-P (Ziermans et al., 2009). These differences
may reflect different maturational ages of the brain
across these two populations or may alternatively be
due to a lower true-positive rate for psychosis in
paediatric CHR-P samples due to more nonspecific
and overlapping phenomenologies of concurrently
emerging psychiatric disorders (Gerstenberg et al.,
2015, 2016; Kelleher et al., 2012; Schimmelmann,
Michel, Martz-Irngartinger, Linder, & Schultze-Lut-
ter, 2015).
The area of discovery of effective preventive treat-
ments for adolescents at CHR-P has received less
empirical evidence. The relevance of effective pre-
vention in this population is unquestionable because
a FEP at an earlier age may translate into a worse
long-term prognosis (Diaz-Caneja et al., 2015) and
reduced cost-effectiveness (Fusar-Poli, Frascarelli,
et al., 2015; Mihalopoulos, Harris, Henry, Harrigan,
& McGorry, 2009). Unfortunately, there are only two
RCTs specifically investigating the efficacy of pre-
ventive psychotherapeutic interventions (cognitive
behavioural therapy vs. nondirective reflective lis-
tening therapy) for adolescents at CHR-P (Stain
et al., 2016). There is no evidence that this treatment
is effective. Another RCT found promising results for
omega-3 fatty acid supplementation (Amminger
et al., 2010), but this finding was likely a false
positive as it was not replicated in a subsequent
confirmatory larger RCT in the adult population
(McGorry et al., 2017). Overall, there is insufficient
evidence to recommend one specific treatment over
the others to prevent the transition to psychosis in
this population, in line with current evidence in this
field (Davies et al., 2018; Devoe, Farris, Townes, &
Addington, 2019; Fusar-Poli et al., 2020). Other
RCTs suggest that family interventions may be
particularly effective in the paediatric CHR-P popu-
lation improving attenuated prepsychotic symptoms
(Miklowitz et al., 2014; Tsai et al., 2015). However,
these promising findings have not been replicated,
and future interventional research is urgently
needed to confirm their robustness and address this
gap in knowledge.
This study has several limitations. First, the mean
age of the included samples was 15.6 but ranged
from 11.7 to 17.9 years, which was highly variable,
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and some studies included adult participants. How-
ever, since the CHR-P paradigm is essentially tran-
sitional, the 18 years age threshold does not work
well. Differences in terms of neurodevelopment
between younger children and older adolescents
could exist, and this could complicate interpretation
of the results. We have mitigated this issue by
conducting sensitivity analyses restricted in under-
age populations. Second, the included studies were
very heterogeneous not only in their design and
methodology but also in their quality. We have,
therefore, carefully reported the study quality. Third,
the number of participants per study was modest,
with only five studies including >100 CHR-P individ-
uals (Auther et al., 2012; Chung et al., 2018;
Miklowitz et al., 2014; Moskow et al., 2016; Velthorst
et al., 2018). To overcome this problem, we per-
formed meta-analyses whenever possible. Finally,
most of the studies were performed in specific
psychiatric services and therefore represent a help-
seeking clinical sample; this is well known to
increase comorbidities, the necessity of treatment
and risk enrichment (Fusar-Poli, Rutigliano, et al.,
2016; Fusar-Poli, Schultze-Lutter, et al., 2016).
Young individuals without comorbid disorders, func-
tional impairments and help-seeking behaviour are
less likely to be referred for CHR-P assessments
(Fusar-Poli, Sullivan, Shah, & Uhlhaas, 2019).
Overall, this study described the core clinical
characteristics of CHR-P adolescents and sum-
marised the available instruments that can be used
by clinicians to detect them. This review highlights
the core outcomes presented by this vulnerable
population and the limited evidence for effective
interventions. The evidence appraised here should
be used as a benchmark to conduct future research
in children and adolescents at risk for psychosis.
Conclusions
The CHR-P paradigm in adolescents has shown to be
useful and widely accepted. Although it is currently
possible to detect and formulate a group-level prog-
nosis in adolescents at risk for psychosis, effective
intervention for this subgroup should be better
identified.
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Key points
 The clinical high risk for psychosis paradigm involves detecting, formulating a prognosis and offering
interventions to those aged 12–18.
 This study demonstrates that it is feasible to detect and formulate a prognosis in the subgroup of adolescents
at risk for psychosis aged 12–18.
 Evidence of effective interventions to prevent the onset of psychosis in adolescents aged 12–18 is lacking.
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